Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProQuad and Infanrix hexa Concomitant Administration in Children
NCT00432042Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Primary completion
- Mar 2008
- Modality
- Live Attenuated Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of varicella virus vaccine live in measles, mumps, rubella and 7 more (3 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Meeting Antibody Response Rate Criteria to Measles, Mumps, Rubella, and Varicella at 42 days, Percentage of Participants Meeting Post-vaccination Antibody Response Rates to Hepatitis B and Haemophilus Influenzae Type B at 42 days and 1 more. Started Jan 2007; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
measlesmumpsrubellavaricella (VZV)diphtheria
Beyond the preview
Go deeper on NCT00432042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432042.